ASCO 2025 | Predictive biomarkers for T-DXd response in metastatic breast cancer
Paolo Tarantino, MD, Dana-Farber Cancer Institute, Boston, MA, comments on a quantitative pre-treatment evaluation of HER2 and topoisomerase 1 (Topo1) expression as predictors of response to trastuzumab deruxtecan (T-DXd) in patients with metastatic breast cancer. Using HER2DX and RPPA assays, higher HER2 mRNA and protein levels were associated with longer time to next treatment in both HER2-positive and HER2-negative disease. Conversely, elevated Topo1 protein levels correlated with poorer outcomes in HER2-negative cases, supporting biomarker-driven treatment strategies. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
